Clinical utility of head computed tomography scan during systemic therapy for metastatic renal cell carcinoma

Abstract

The utility of brain metastasis screening in asymptomatic metastatic renal cell carcinoma is controversial. Our study evaluated the utility of routine head computed tomography during systemic therapy. Methods: We retrospectively investigated 152 metastatic renal cell carcinoma patients who did not initially have brain metastasis at Yamagata University Hospital from January 2008 to July 2019. Patients who routinely received head computed tomography scan together with routine contrast-enhanced chest/abdominal/pelvic computed tomography scan every 2-4 months during systemic therapy ("Routine head computed tomography" group, n = 95) and patients without routine head computed tomography ("No routine head computed tomography" group, n = 57) were compared. Results: Brain metastasis occurred in 16 patients in the "Routine head computed tomography" group and six patients in the "No routine head computed tomography" group. There was no statistical difference in overall survival after metastatic renal cell carcinoma diagnosis between groups (53.4 vs 37.3 months, respectively, P = 0.357) and neurological symptom-free survival after metastatic renal cell carcinoma diagnosis (53.4 vs 36.6 months, P = 0.336). Although there was no statistical difference on incidence of unrecovered neurological symptom (25.0% vs 50.0%, P = 0.334), fewer patients in the "Routine head computed tomography" group required craniotomy (0% vs 66.7%, P = 0.002). In the "No routine head computed tomography" group, the neurological symptom resolved for all patients without craniotomy. Conclusions: Routine head computed tomography during systemic therapy for metastatic renal cell carcinoma is not significantly associated with improved brain metastasis prognosis. However, routine head computed tomography enables brain metastasis diagnosis in the asymptomatic phase, which can avoid craniotomy.

Surgical and focal treatment for metastatic renal cell carcinoma: A literature review

“…Approximately 8–30% of mRCC patients develop brain metastasis 65–70 . In addition, the most common site as a new lesion during ICI therapy was reported to be the brain 71 .…”

“…Approximately 8-30% of mRCC patients develop brain metastasis. [65][66][67][68][69][70] In addition, the most common site as a new lesion during ICI therapy was reported to be the brain. 71 In the NIVOREN phase 2 trial that assessed the activity and safety of nivolumab in patients with mRCC who failed TT, patients with asymptomatic brain metastases at the initiation of nivolumab were evaluated.…”